<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing recommendations for antiviral agents for prevention of influenza in children and adolescents&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing recommendations for antiviral agents for prevention of influenza in children and adolescents<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing recommendations for antiviral agents for prevention of influenza in children and adolescents<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup span="5" width="15%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">Drug/formulation</td> <td class="subtitle1" colspan="5">Dosing recommendations for prophylaxis</td> </tr> <tr> <td class="divider_bottom" rowspan="3"> <p><strong>Oseltamivir (Tamiflu)</strong>*</p> <ul> <li>30 mg capsule</li> <li>45 mg capsule</li> <li>75 mg capsule</li> <li> 6 mg/mL suspension<sup>¶</sup></li> </ul> </td> <td colspan="4"><strong>1 through 12 years</strong></td> <td><strong>≥13 years</strong></td> </tr> <tr> <td class="indent1">≤15 kg</td> <td>&gt;15 to 23 kg</td> <td>&gt;23 to 40 kg</td> <td>&gt;40 kg</td> <td class="divider_bottom indent1" rowspan="2">75 mg orally once daily</td> </tr> <tr class="divider_bottom"> <td class="indent1">30 mg orally once daily</td> <td>45 mg orally once daily</td> <td>60 mg orally once daily</td> <td>75 mg orally once daily</td> </tr> <tr> <td class="divider_bottom" rowspan="2"> <p><strong>Zanamivir</strong><sup>Δ</sup> <strong>(Relenza)</strong></p> <ul> <li> 5 mg per inhalation (Diskhaler)</li> </ul> </td> <td colspan="5"><strong>Children ≥5 years and adults</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="5"> <ul> <li>2 inhalations (10 mg total per dose)</li> </ul> </td> </tr> <tr> <td rowspan="2"> <p><strong>Baloxavir (Xofluza) for postexposure prophylaxis</strong><sup>◊</sup></p> <ul> <li>20 mg tablet</li> <li> 40 mg tablet</li> <li>2 mg/mL suspension</li> </ul> </td> <td colspan="5"><strong>Children ≥5 years and adults</strong><sup>§</sup></td> </tr> <tr> <td class="indent1" colspan="5"> <ul> <li>&lt;20 kg (oral suspension) – 2 mg/kg single dose orally</li> <li>20 to &lt;80 kg (oral suspension or tablet) – 40 mg single dose orally</li> <li>≥80 kg (oral suspension or tablet) – 80 mg single dose orally</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content related to chemoprophylaxis for seasonal influenza in children. The choice of agent for prophylaxis depends upon the age of the child, susceptibility patterns of circulating strains (if known), and concern about risk of emergent resistance. The duration of prophylaxis for oseltamivir and zanamivir varies with the clinical circumstances. Refer to UpToDate content for additional details, including indications for chemoprophylaxis and dosing recommendations for children younger than 1 year.</div><div class="graphic_footnotes"><p>* Dose adjustment is necessary for patients with decreased or decreasing glomerular filtration rate.</p>
<p>¶ When dispensing the oral suspension of oseltamivir, pharmacists or other health care personnel should provide an oral syringe that can accurately measure the prescribed milliliter (mL) dose.</p>
<p>Δ Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators.</p>
<p>◊ Avoid administering baloxavir with milk, other dairy, antacids, or mineral supplements (eg calcium, iron, magnesium), which can significantly decrease oral bioavailability<sup>[2]</sup>.</p>
§ Baloxavir is available in Japan for postexposure prophylaxis in children &lt;12 years of age who weigh &gt;20 kg. Refer to Japanese prescribing information for dosing information for children &lt;12 years of age.</div><div class="graphic_reference">References:
<ol>
<li>American Academy of Pediatrics. Non-HIV antiviral drugs. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.930.</li>
<li>Xofluza (baloxavir marboxil). US Food and Drug Administration (FDA) approved product information. Revised August 2022. Available online at: <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</a> (Accessed on August 16, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 61888 Version 22.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
